多西紫杉醇联合顺铂与联合奈达铂化疗方案治疗晚期非小细胞肺癌的临床观察

Clinical observation of the regimen for docetaxel combined with cisplatin and dedaplain chemotherapy in the treatment of advanced non-small cell lung cancer

目的:观察多西紫杉醇联合顺铂化疗方案与多西紫杉醇联合奈达铂方案治疗中晚期(Ⅲ_B、Ⅳ期)非小细胞肺癌(non small cell lung cancer,NSCLC)的疗效及不良反应。方法:62例中晚期非小细胞肺癌患者,其中多西紫杉醇联合顺铂化疔方案组(A组)32例,多西紫杉醇联合奈达铂方案组(B组)30例。结果:A组有效率(37.5%) B组有效率(38.7%)无显著差异(P>0.05);A组胃肠道反应(77.4%)发生率明显高于B组(60%)(P<0.01);两组肾脏毒性无明显差异;两组白细胞下降发生率分别为50%和76.67%,条达铂组明显(P<0.05);血小板下降A组(6.3%)较B组(26.67%)显著(P<0.05)。结论:多西紫杉醇联合奈达铂方案治疗中晚期(ⅢBⅣ期)非小细胞肺癌的有效率不低于多西紫杉醇联合顺铂方案,胃肠道毒性较轻,不良反应主要为骨髓抑制及过敏反应。

Objective： To detect the efficacy and the side effect of the regimen for docetaxel combined with cisplatin and Nedaplatin chemotherapy in the treatment with advanced non-small cell lung cancer. Methods： A total of 62 patients with advanced non-small cell lung cancer were divided into the docetaxel combined with cisplatin group （group A, n =32） and the docetaxel combined with Nedaplatin group （group B n =30）. Results： The efficacy of group A was 37.5% and group B was 38.7%, there was no significant difference between the two groups in curative effect （P 〉0.05）. A higher response rate of digestive reaction and nephrotoxicity （77.4%） occurred in group A, compared to that occurred in group B（60%）, with a significant difference between the two groups （P 〈0.01）. There was no significant difference between two groups in the toxicity of kidney. There was a lower incidence of leucopenia response rate （50%） in group A than in group B（76.67%）, with a significant difference between the groups （P 〈0.05）. There was a lower thrombocytopenia response rate （6.3%） in group A than in group B（26.67%）, with a significant difference between the groups （P 〈0.05）. Conclusions： There is no significant difference between docetaxel combined with cisplatin group and nedaplain group and there is a lower digestive reaction and nephrotoxicity response rate in cisplatin group. And the main adverse reaction was myelosuppression and allergic reaction.